In a 58-year-old male with stage 3 chronic kidney disease, heart failure with reduced ejection fraction, hypertension, dyspnea on exertion, atrial fibrillation, non‑ischemic cardiomyopathy, and chronic congestive heart failure, who now has erythrocytosis (hemoglobin 18.7 g/dL, hematocrit 55 %, platelet count 141 ×10⁹/L, white‑cell count 5.9 ×10⁹/L, basophils 1.2 %, normocytic normochromic red cells, RBC count 6.04 ×10⁶/µL), what are the next steps in evaluation and management?

Immediate Workup for Secondary Erythrocytosis

This patient requires urgent evaluation for secondary causes of erythrocytosis, starting with arterial blood gas, oxygen saturation measurement, serum erythropoietin level, and assessment for obstructive sleep apnea—therapeutic phlebotomy is NOT indicated at this hemoglobin level.

Initial Diagnostic Approach

Your patient has significant erythrocytosis (Hgb 18.7 g/dL, Hct 55%) that is paradoxical given his stage 3 CKD and heart failure, where anemia would be expected 1. This demands investigation for secondary causes before any intervention.

Essential First-Line Tests

• Arterial blood gas with co-oximetry: Measure PaO2, oxygen saturation, and carboxyhemoglobin levels to identify hypoxemia or carbon monoxide exposure
• Serum erythropoietin level: Elevated EPO suggests secondary polycythemia; low/normal EPO raises concern for polycythemia vera 2
• Sleep study evaluation: Given his heart failure, atrial fibrillation, and dyspnea, obstructive sleep apnea is highly likely and can drive erythrocytosis 3
• Renal imaging (ultrasound with Doppler): Rule out renal artery stenosis or renal masses producing EPO 2

Critical Context

The combination of heart failure with reduced ejection fraction and erythrocytosis is unusual and concerning. Most HFrEF patients develop anemia due to chronic disease, hemodilution, and relative erythropoietin resistance 4, 5. His elevated hemoglobin actually increases blood viscosity and cardiac workload, potentially worsening his heart failure symptoms.

When Phlebotomy Is Appropriate (And When It's Not)

Do NOT perform phlebotomy at this hemoglobin level. Therapeutic phlebotomy is only indicated when hemoglobin exceeds 20 g/dL AND hematocrit exceeds 65% WITH symptoms of hyperviscosity (headache, poor concentration) and confirmed absence of dehydration 6. Your patient's Hgb of 18.7 g/dL and Hct of 55% fall well below these thresholds.

Why Avoiding Premature Phlebotomy Matters

Repeated phlebotomies deplete iron stores, create microcytic iron-deficient red cells with reduced oxygen-carrying capacity and deformability, and paradoxically increase stroke risk 6. This is particularly dangerous in patients with underlying cardiovascular disease.

Specific Conditions to Evaluate

1. Obstructive Sleep Apnea (Most Likely)

• His heart failure, atrial fibrillation, and dyspnea make OSA highly probable
• Nocturnal hypoxemia drives compensatory erythrocytosis
• Formal polysomnography is essential 3

2. Chronic Hypoxemia from Heart Failure

• Right-to-left shunting or severe pulmonary hypertension can cause hypoxemia
• Check resting oxygen saturation and consider echocardiography to assess for intracardiac shunts 6

3. Renal Pathology

• Renal artery stenosis or renal cell carcinoma can produce excess EPO
• His stage 3 CKD warrants renal ultrasound with Doppler 2

4. Smoking/Carbon Monoxide Exposure

• Measure carboxyhemoglobin level
• Even passive smoke exposure can elevate carboxyhemoglobin 2

5. Polycythemia Vera (Less Likely but Must Exclude)

• Low/normal EPO with elevated hemoglobin suggests PV
• Would require JAK2 mutation testing and hematology referral 2

Management of Concurrent Heart Failure and CKD

While investigating the erythrocytosis, optimize his heart failure management carefully given his CKD:

Medication Considerations

• Continue ACE inhibitors/ARBs/ARNI: Safe and effective in stage 3 CKD (eGFR ≥30 mL/min/1.73 m²) 7, 8
• Beta-blockers: Continue at target dose; bisoprolol may accumulate but titrate to clinical response 8
• SGLT2 inhibitors: Strongly recommended—effective for HFrEF even with eGFR ≥25-30 mL/min/1.73 m² 7, 9
• Mineralocorticoid receptor antagonists: Use cautiously with low starting dose (6.25-12.5 mg daily) given CKD; monitor potassium closely 8

Monitoring Parameters

• Check serum creatinine and potassium within 1-3 days after any medication adjustment 10
• Accept small increases in creatinine (up to 30% from baseline) if clinically stable—this does not mandate stopping life-saving therapies 7
• Monitor for volume status changes that could affect both heart failure and renal function 11

Common Pitfalls to Avoid

1. Do not phlebotomize based solely on hemoglobin/hematocrit numbers without symptoms of hyperviscosity and meeting threshold criteria (Hgb >20 g/dL, Hct >65%) 6

2. Do not assume this is polycythemia vera without measuring EPO and excluding secondary causes—secondary polycythemia is far more common 2

3. Do not withhold guideline-directed medical therapy for heart failure due to stage 3 CKD—these medications are safe and beneficial at this level of renal function 7, 8

4. Do not overlook sleep apnea—it is extremely common in heart failure patients and a readily treatable cause of erythrocytosis 3

5. Do not forget to assess hydration status—dehydration can spuriously elevate hemoglobin and hematocrit (hemoconcentration) 6

Next Steps Algorithm

1. Immediate: Order ABG with co-oximetry, serum EPO, renal ultrasound with Doppler
2. Within 1 week: Arrange sleep study evaluation
3. If EPO elevated: Focus on treating underlying hypoxemia (OSA treatment, optimize oxygenation)
4. If EPO low/normal: Refer to hematology for polycythemia vera workup (JAK2 mutation, bone marrow biopsy if indicated)
5. Continue: Optimize heart failure medications per guidelines, with close monitoring of renal function and electrolytes

The elevated hemoglobin in this clinical context is a red flag requiring systematic investigation, not an indication for phlebotomy.